-Top executive for Allergen , the creator of Botox, left the company to become CEO in May 2018, days before the de facto FDA approval -More than 200 physician KOLs are invested in Evolus's parent company -First 900 kDa neurotoxin to be filed with the FDA since Botox -DPW-450 is projected to be 20-25% cheaper then Botox -Approved by the FDA recently -Massive...
Market Cap 2.86B Enterprise Value 1.94B Price/Sales 484.27 I think it is getting a little too far ahead of itself at this point. The Cramer pump is suspicious, especially considering the timing. The reason I'm only adding 1/4th is because the momentum is still strong, and it could rally up to $20.00.
Established resistance twice now, stochastic and MACD also giving slightly bearish signals